GRAND CAYMAN - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm specializing in RNA interference (RNAi) therapies, has reported enhanced results from its Phase 2 trial of LODER™ in treating locally advanced pancreatic cancer (LAPC). The study indicated a 56% objective response rate (ORR) among patients, with a 67% increase in resectability for previously non-resectable tumors.
The trial, which included 48 participants across the U.S. and Israel, showed that LODER, when used with standard-of-care chemotherapy, could significantly improve the chances of surgical intervention in cases where pancreatic cancer was deemed inoperable. This development could potentially alter the course of treatment for patients with LAPC, a typically aggressive form of cancer.
LODER's previous data had already suggested a 9.3-month improvement in overall survival compared to chemotherapy alone. The latest findings underscore the treatment's potential to enhance surgical outcomes further.
Building on LODER's success, Silexion is advancing its next-generation product, SIL-204, which targets a wider array of KRAS mutations associated with various cancers. Preclinical models have shown SIL-204 to have improved stability and an enhanced ability to reach and silence the KRAS oncogene effectively.
Ilan Hadar, Chairman and CEO of Silexion, expressed optimism about the new findings, highlighting LODER's impact on tumor resectability and the promising profile of SIL-204. The company's focus remains on addressing KRAS-driven cancers and improving patient outcomes.
These results are part of Silexion's ongoing commitment to innovative cancer treatment strategies, particularly for challenging cases like LAPC. The company continues to explore the capabilities of RNAi therapies in oncology.
The information provided is based on a press release statement from Silexion Therapeutics Corp.
In other recent news, Silexion Therapeutics Corp announced the immediate resignation of board member Ilan Shiloah. Shiloah's decision to step down was attributed to competing time demands and not due to any disagreements with the company's operations, policies, or practices. His departure leaves vacancies on the audit, compensation, and corporate governance and nominating committees where he served.
Shiloah joined the board following the company's business combination transaction in August 2024, and his tenure on the board was brief. His resignation follows the company's recent merger with Moringa Acquisition Corp in April 2024.
It's worth noting that the company, formerly known as Biomotion Sciences, changed its name to Silexion Therapeutics Corp on May 6, 2024. These are among the recent developments within the company, shedding light on its evolving corporate landscape.
InvestingPro Insights
Amidst the promising clinical trial results for its LODER™ therapy, Silexion Therapeutics Corp. (NASDAQ: SLXN) has experienced a tumultuous period in the stock market. An InvestingPro Tip indicates that the stock is currently in oversold territory according to the Relative Strength Index (RSI), suggesting that the market may have reacted too negatively to recent events, potentially creating an entry point for investors who believe in the company's long-term prospects. Additionally, SLXN has been identified as trading with high price volatility, which could mean that investors should be prepared for significant price swings when investing in this stock.
In terms of market performance, InvestingPro Data shows a sharp decline in the company's stock price. Silexion's market capitalization stands at a modest 6.4 million USD, reflecting the scale of the company within the biotech sector. The stock has taken a significant hit over the last week, with a price total return of -19.65%, and this downward trend extends over longer periods, with a -45.38% return over the last month, and a staggering -93.45% over the last three months. These metrics underscore the challenges faced by the company in the market, despite the clinical advancements it is making.
For those interested in a deeper analysis, there are additional InvestingPro Tips available for SLXN at https://www.investing.com/pro/SLXN, providing a comprehensive view of the company's financial health and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.